Four Scientific Sessions Highlighted HIFU for Treatment of Prostate Cancer

HIFU Featured in Plenary Lecture and Two Moderated Posters at Engineering and Urology Society Meeting

Significant Interest in both HIFU and ESWL Technologies at EDAP Booth

LYON, France, May 14, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, highlighted its positive reception at the American Urological Association (AUA) 2013 Annual Meeting, held in San Diego on May 4-8, 2013. At the meeting, four scientific abstracts were presented regarding the outcomes for HIFU treatment of prostate cancer, and two regarding clinical use of the Sonolith lithotripter and its exclusive ultrasound Visio Track^® localization system. Two of the HIFU posters, #1208 and #1496, entitled The importance of biopsies in ablation therapies for prostate cancer: Start of salvage treatment for persistent positive biopsies after HIFU and HIFU treatment outcomes for localized prostate cancer from the first European centers, respectively, received Best Poster awards from the AUA.

On May 4, 2013, at the 28th Annual Meeting of the Engineering and Urology Society, held in conjunction with AUA, two posters highlighting HIFU were presented by Pr. Christian Chaussy of the University Regensburg, Germany. In addition, Pr. Chaussy gave an invited plenary session on long term results of HIFU for localized prostate cancer from his over 15 year experience with the procedure. 

Mr. Oczachowski, EDAP's Chief Executive Officer, said, "We are proud that two of our Ablatherm-HIFU posters received the best poster award during the AUA. This is clear academic recognition of HIFU as a valuable technology for treating prostate cancer and reflects positively on the high level of research supporting Ablatherm-HIFU. This is a key differentiation point for EDAP, and reinforces our established leadership in HIFU for the treatment of prostate cancer both from a technological and clinical standpoint."

Mr. Oczachowski continued, "The high level of traffic that we experienced at our booth at the AUA meeting clearly demonstrates the heightened level of interest and enthusiasm that U.S. doctors and other urology stakeholders have in EDAP's leading edge HIFU technology. In addition, our Sonolith i-move demonstrations were very well attended. Our strategy to focus on the US market for both technologies is starting to produce results as we were extremely visible during this event, the largest urological meeting in the US."

About EDAP TMS SA

EDAP TMS SA markets Ablatherm® for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements that involve risks and uncertainties. Such statements are based on management's current expectations and are subject to a number of uncertainties, including the uncertainties of the regulatory process, and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

CONTACT: Blandine Confort

         Investor Relations / Legal Affairs

         EDAP TMS SA

         +33 4 72 15 31 72

         bconfort@edap-tms.com



         Investors:

         Stephanie Carrington

         The Ruth Group

         646-536-7017

         scarrington@theruthgroup.com

News Provided by Acquire Media